<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9392">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05698758</url>
  </required_header>
  <id_info>
    <org_study_id>K-2022-160-01</org_study_id>
    <nct_id>NCT05698758</nct_id>
  </id_info>
  <brief_title>Intranasal Dexmedetomidine for Adult Patients Undergoing Phacoemulsification Cataract Surgery</brief_title>
  <official_title>A Randomized Controlled Trial of Intranasal Dexmedetomidine for Adult Patients Undergoing Phacoemulsification Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou First People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators designed this study to examine whether the intranasal dexmedetomidine, as a&#xD;
      preoperative drug, could improve the satisfaction of adult patients undergoing&#xD;
      phacoemulsification cataract surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, double-blind, randomized controlled study. Patients over 65 years old&#xD;
      were selected for phacoemulsification combined with intraocular lens implantation under&#xD;
      topical anesthesia. Participants were randomly divided into two groups: dextrometropine group&#xD;
      and placebo group, and were masked until the end of this study. Approximately 45 - 60 minutes&#xD;
      before surface anesthesia, patients in the dextrometropine group were given dextrometropine&#xD;
      (1.0μg.kg-1), patients in the placebo group were given the same amount of saline. The primary&#xD;
      end point of this study is the patient satisfaction. Patient satisfaction was assessed using&#xD;
      a 3-point satisfaction score on a scale. Anxiety of perioperative patients was assessed using&#xD;
      a 4-point anxiety score on a scale. Secondary endpoints include blood pressure, heart rate,&#xD;
      blood oxygen saturation, operation time, operative complications and adverse drug reactions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2023</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall patients satisfaction with preoperative sedation</measure>
    <time_frame>Operation day</time_frame>
    <description>Patient satisfaction was assessed using a 3-point satisfaction score on a scale (1 = highly satisfactory, 2 = acceptable, and 3 = unacceptable). The minimum value is 1 and maximum is 3. Higher scores mean a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anxiety of perioperative patients</measure>
    <time_frame>Operation day</time_frame>
    <description>Anxiety of perioperative patients was assessed using a 4-point anxiety score (1 = combative, 2 = anxious, 3 = calm, and 4 = amiable). The minimum value is 1 and maximum is 4. Higher scores mean a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of preoperative sedation on patients' vital signs and operation time</measure>
    <time_frame>Perioperative period</time_frame>
    <description>Blood pressure, heart rate, blood oxygen saturation, operation time, operative complications and adverse drug reactions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Cataract</condition>
  <condition>Preoperative Sedation</condition>
  <arm_group>
    <arm_group_label>dextrometropine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 45 - 60 minutes before cataract surgery, patients in the dextrometropine group were given dextrometropine (1.0μg.kg-1).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Approximately 45 - 60 minutes before cataract surgery, patients in the placebo group were given 0.9% sodium chloride solution (1.0μg.kg-1).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextrometropine and 0.9% sodium chloride solution</intervention_name>
    <description>Intranasal dexmedetomidine or 0.9% sodium chloride solution as a sedative premedication for patients undergoing cataract surgery</description>
    <arm_group_label>dextrometropine group</arm_group_label>
    <arm_group_label>placebo group</arm_group_label>
    <other_name>Dexmedetomidine Hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Cataract patients over 65 years scheduled for elective&#xD;
        phacoemulsification and intraocular lens implantation in Department of Ophthalmology,&#xD;
        Guangzhou First People's Hospital will be recruited in this study. Recruited patients shall&#xD;
        own normal intelligence and understanding capability and their best corrected visual acuity&#xD;
        more than 0.1 in either eye.&#xD;
&#xD;
        Exclusion Criteria: 1) a known allergy or hypersensitivity to dextrometropine or other&#xD;
        anesthetics; 2) a previous history of heart disease; 3) a heart rate (HR) &lt;45 beats per&#xD;
        minute (bpm); 4) a second- or third-degree atrioventricular block; 5) patients on&#xD;
        antihypertensive drugs, such as α-methyldopa, clonidine, or other α2-adrenergic agonists;&#xD;
        6) asthma; 7) sleep apnea syndrome; 8) organ dysfunction; 9) patients with mental illness;&#xD;
        and 10) the long-term use of sedatives and analgesics.&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuehong Zhang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangzhou First People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuehong Zhang, PhD</last_name>
    <phone>86-02081048225</phone>
    <email>carmenzhangyh@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhimeng Zhang, PhD</last_name>
    <phone>86-02081048225</phone>
    <email>598527019@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangzhou First People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510180</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuehong Zhang, MD, PhD</last_name>
      <phone>+862081048225</phone>
      <email>carmenzhangyh@163.com</email>
    </contact>
    <investigator>
      <last_name>Yuehong Zhang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>January 16, 2023</study_first_submitted>
  <study_first_submitted_qc>January 16, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2023</study_first_posted>
  <last_update_submitted>February 4, 2023</last_update_submitted>
  <last_update_submitted_qc>February 4, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou First People's Hospital</investigator_affiliation>
    <investigator_full_name>Yuehong Zhang</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Cataract</keyword>
  <keyword>Preoperative sedation</keyword>
  <keyword>Dextromethoridine</keyword>
  <keyword>Patient satisfaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

